ClinicalTrials.gg
WithdrawnNCT03563170Updated Mar 18, 2021

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

A Phase 1/2 interventional study of ETBX-011 and GI-4000 in Hepatocellular Carcinoma Non-resectable and Hepatocellular Carcinoma Recurrent, sponsored by ImmunityBio, Inc.. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-18.

Sponsored by ImmunityBio, Inc. · Phase 1/2, Interventional, and Treatment

Why this study was withdrawn
Enrollment not initiated

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 926 studies in Carcinoma, Hepatocellular with a site in United States — 160 open to participants now, 245 under way, 17 of them phase 3. Carcinoma, Hepatocellular · United States.

Enrollment
737th of 775
0 · median 36
Started
2018
with 48 others
Phase 1/2
112 of 926
29 open now
Registered
552nd of 926
by date

Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, this one is the 737th largest by enrollment of the 775 interventional ones that give a count, is one of 49 that started in 2018, is one of 112 in phase 1/2, and was the 552nd registered.

Carcinoma, Hepatocellular

3,652 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,065 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

160 of the 926 studies in Carcinoma, Hepatocellular with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 741 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 251 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 926 studies in Carcinoma, Hepatocellular with a site in United States, or all of them as a file.
02

Study summary

This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with advanced, unresectable, and untransplantable HCC.

Read the detailed description

Treatment will be administered in two phases, an induction and a maintenance phase. Subjects will continue induction treatment for up to 1 year. Those who have a CR in the induction phase will enter the maintenance phase of the study. Subjects who experience ongoing SD or an ongoing PR at 1 year may enter the maintenance phase at the Investigator's and Sponsor's discretion. Subjects may remain in the maintenance phase of the study for up to 1 year. Treatment in the study will be discontinued if the subject experiences confirmed PD or unacceptable toxicity (not corrected with dose reduction), withdraws consent, undergoes liver transplantation or surgical resection, or if the Investigator feels it is no longer in the subject's best interest to continue treatment. Subjects with an initial assessment of PD may, at the discretion of the Investigator, continue to receive study treatment until PD is confirmed. The maximum time on study treatment is 2 years.

03

Conditions studied

  • Hepatocellular Carcinoma Non-resectable
  • Hepatocellular Carcinoma Recurrent

Keywords

  • HCC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years.
  2. Able to understand and provide a signed that fulfills the relevant IRB or Independent Ethics Committee (IEC) guidelines.
  3. -confirmed advanced, unresectable and untransplantable HCC.
  4. (ECOG) performance status of 0 to 1.
  5. Have at least 1 of ≥ 1.0 cm.
  6. Must have class A only.
  7. Must have a recent formalin-fixed, paraffin-embedded (FFPE) tumor specimen following the conclusion of the most recent anticancer treatment and be willing to release the specimen for prospective and exploratory tumor molecular profiling. If an historic specimen is not available, the subject must be willing to undergo a biopsy during the screening period, if considered safe by the Investigator. If safety concerns preclude collection of a biopsy during the screening period, a tumor biopsy specimen collected prior to the conclusion of the most recent anticancer treatment may be used.
  8. Must be willing to provide blood samples prior to the start of treatment on this study for prospective tumor molecular profiling and exploratory analyses.
  9. Must be willing to provide a tumor biopsy specimen 8 weeks after the start of treatment for exploratory analyses, if considered safe by the Investigator.
  10. Ability to attend required study visits and return for adequate follow-up, as required by this protocol.
  11. Agreement to practice effective for female subjects of and non-sterile males. Female subjects of child-bearing potential must agree to use effective contraception for up to 1 year after completion of therapy, and non-sterile male subjects must agree to use a condom for up to 4 months after treatment. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), two forms of barrier methods (eg, condom, diaphragm) used with spermicide, intrauterine devices (IUDs), and abstinence.
  12. Any prior locoregional therapy allowed.

    Phase 1b only

  13. Must have progressed or experienced unacceptable toxicity on sorafenib prior to enrollment in the study.

    Phase 2 single-arm component only

  14. Must have progressed on or after sorafenib monotherapy in the randomized phase 2 portion of the study OR progressed or experienced unacceptable toxicity on sorafenib prior to enrollment on the study.

Exclusion criteria

Exclusion Criteria:

  1. Serious uncontrolled concomitant disease that would contraindicate the use of the drug used in this study or that would put the subject at high risk for treatment-related complications.
  2. Systemic disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, or autoimmune disease associated with lymphoma).
  3. History of organ transplant requiring .
  4. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
  5. Inadequate organ function, evidenced by the following laboratory results:

    1. \< 1,000 cells/mm\^3
    2. Medically uncorrectable grade 3 anemia ( \< 8 g/dL).
    3. count \< 75,000 cells/mm\^3.
    4. Total greater than the (ULN; unless the subject has documented Gilbert's syndrome).
    5. (AST [SGOT]) or alanine aminotransferase (ALT [SGPT])

      ≥ 2.5 × ULN (≥ 5 × ULN in subjects with liver ).

    6. Alkaline phosphatase levels > 2.5 × ULN (> 5 × ULN in subjects with liver metastases, or >10 × ULN in subjects with bone metastases).
    7. Serum creatinine > 2.0 mg/dL or 177 μmol/L.
    8. (INR) ≥ 2.0
    9. Serum anion gap > 16 mEq/L or arterial blood with pH \< 7.3.
  6. Uncontrolled hypertension (systolic > 160 mm Hg and/or diastolic > 110 mm Hg) or (ie, active) cardiovascular disease, cerebrovascular accident/stroke, or myocardial infarction within 6 months prior to first study medication; unstable angina; congestive heart failure of grade 2 or higher; or serious cardiac arrhythmia requiring medication.
  7. Episode of portal hypertension-related GI bleeding within prior 6 months.
  8. Serious myocardial dysfunction defined by echocardiogram (ECHO) as absolute (LVEF) 10% below the institution's lower limit of normal (LLN).
  9. Dyspnea at rest due to complications of advanced or other disease requiring continuous oxygen therapy.
  10. Positive results of screening test for (HIV).
  11. Participants with dual active virus (HBV) infection (hepatitis B surface antigen [HBsAg] positive [+] and /or detectable HBVDNA) and virus (HCV) infection (anti-HCV antibody [Ab] [+] and detectable HCV ribonucleic acid [RNA]) at study entry. Subjects with chronic infection by HCV who are treated with anti-hepatitis B therapy (successfully or treatment failure) or untreated are allowed on study. Controlled (treated) hepatitis B subjects will be allowed if they meet the following criteria:

    1. Antiviral therapy for HBV must be given for at least 12 weeks and HBV viral load must be less than 100 IU/mL prior to first dose of study drug; subjects on active HBV therapy with viral loads under 100 IU/mL should stay on the same therapy throughout study treatment.
    2. Subjects who are positive for anti-hepatitis B core Abs (HBc[+]), negative for HBsAg, negative for anti-hepatitis B surface Ab (HBs[-]), and have a HBV viral load under 100 IU/mL do not require HBV anti-viral prophylaxis.
    3. Subjects with successful HCV treatment are allowed as long as there are at least 4 weeks between achieving sustained viral response (SVR) and start of study drug.
  12. Current chronic daily treatment (continuous for > 3 months) with systemic (dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic reaction or anaphylaxis in subjects who have known contrast allergies is allowed.
  13. Known to any component of the study medication(s).
  14. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug reaction with any of the study medications.
  15. Concurrent or prior use of a strong cytochrome P450 (CYP)3A4 inhibitor (including ketoconazole, itraconazole, posaconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, and grapefruit products) or strong inducers (including phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, and St John's Wort) within 14 days before study day 1.
  16. Concurrent or prior use of a strong CYP2C8 inhibitor (gemfibrozil) or moderate CYP2C8 inducer (rifampin) within 14 days before study day 1.
  17. Participation in an investigational drug study or history of receiving any investigational treatment within 14 days prior to screening for this study, except for testosterone-lowering therapy in men with prostate cancer.
  18. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.
  19. Concurrent participation in any interventional clinical trial.
  20. Pregnant and nursing women.

    Phase 2 randomized component only -

  21. Prior sorafenib treatment.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    NANT Hepatocellular Carcinoma Vaccine

    Phase 1b and 2: The following combination of agents will be administered to subjects assigned to this treatment: Aldoxorubicin HCl, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, N-803, haNK™, avelumab, capecitabine, cetuximab, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, sorafenib tosylate, SBRT.

    Biological: ETBX-011 · Biological: GI-4000 · Biological: haNK for infusion · Biological: avelumab · Drug: Capecitabine · Drug: Cyclophosphamide · Drug: 5-Fluorouracil · Drug: Leucovorin · Drug: nab-Paclitaxel · Drug: Sorafenib · Procedure: SBRT · Biological: Aldoxorubicin hydrochloride · Biological: ETBX-051 · Biological: ETBX-061 · Biological: GI-6207 · Biological: GI-6301 · Drug: Cetuximab · Biological: N-803

  • Active comparator
    Sorafenib Monotherapy

    Phase 2: Sorafenib monotherapy will be administered to subjects with advanced, unresectable, and untransplantable HCC, who have not previously received sorafenib, and who are randomly assigned to receive SOC treatment.

    Drug: Sorafenib

Interventions

  • BiologicalETBX-011

    Ad5 \[E1-, E2b-\]-CEA

  • BiologicalGI-4000

    Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant RAS proteins

  • BiologicalhaNK for infusion

    NK-92 \[CD16.158V, ER IL-2\]

  • Biologicalavelumab

    Recombinant human anti-PD-L1 IgG1 monoclonal antibody

  • 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine

  • anhydrous

  • 5-FU; Fluorouracil

  • Leucovorin calcium salt

  • ABRAXANE® \[paclitaxel protein-bound particles for injectable suspension\] \[albumin-bound\]

  • NEXAVAR® tablets, for oral use

  • ProcedureSBRT

    Stereotactic Body Radiation Therapy

  • BiologicalAldoxorubicin hydrochloride

    HCl

  • BiologicalETBX-051

    Ad5 \[E1-, E2b-\]-Brachyury vaccine

  • BiologicalETBX-061

    Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine

  • BiologicalGI-6207

    CEA yeast vaccine

  • BiologicalGI-6301

    Brachyury yeast vaccine

  • ERBITUX® injection, for IV infusion)

  • BiologicalN-803

    Recombinant human super agonist IL-15 complex \[also known as IL-15N72D:IL- 15RαSu/IgG1 Fc complex\]

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent AEs and SAEs, graded using the NCI CTCAE Version 4.03

    Phase 1b

    Time frame: 2 years

  2. Evaluate the overall safety profile in subjects with advanced, unresectable, untransplantable HCC who have progressed or experienced unacceptable toxicity on prior sorafenib treatment. Measured / reported based on the tumor size imaging per RECIST 1.1.

    Phase 1b

    Time frame: 2 years

  3. Progression Free Survival from baseline to progression, per RECIST 1.1

    Phase 2 Randomized Component

    Time frame: 2 years

  4. Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete Response per RECIST 1.1

    Phase 2 Single Arm Component

    Time frame: 2 years

Secondary outcomes

  1. ORR for Phase 1b and Phase 2 Randomized Component

    Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete response per RECIST 1.1 and irRC

    Time frame: 2 years

  2. PFS for Phase 1b and Phase 2 Single Arm Component

    Progression Free Survival from baseline to progression per RECIST 1.1 and irRC

    Time frame: 1 year

  3. OS for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component

    Overall Survival from first treatment to date of death (any cause)

    Time frame: 2 years

  4. DOR for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component

    Duration of Response from date of first response to date of disease progression or death (any cause), per RECIST 1.1 and irRC

    Time frame: 2 years

  5. DCR for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component

    Disease Control Rate: the number of patients with a CR, PR or SD lasting at least 2 months per RECIST 1.1 and irRC

    Time frame: 1 year

  6. QoL for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component

    Quality of Life as assessed by Patient Reported Outcomes using the FACT-C questionnaire

    Time frame: 1 year

  7. PFS for Phase 2 Randomized Component

    Progression Free Survival from baseline to progression per irRC

    Time frame: 2 years

  8. Safety for Phase 2 Randomized and Single Arm Component

    Incidence of treatment-emergent AEs and SAEs, graded using the NCI CTCAE Version 4.03

    Time frame: 2 years

  9. ORR for Phase 2 Single Arm Component

    Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete response per irRC

    Time frame: 2 years

07

Study locations

1 site
  • Chan Soon-Shiong Institute for Medicine
    El Segundo, California 90245, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Aug 2019, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2018
First posted
Jun 20, 2018
StartActual
May 25, 2018
Primary completionActual
Aug 23, 2019
CompletionActual
Aug 23, 2019
Last update
Mar 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03563170
Lead sponsor
ImmunityBio, Inc.
Responsible party
Sponsor
First posted
Jun 20, 2018
Start date
May 25, 2018
Primary completion
Aug 23, 2019
Completion
Aug 23, 2019
Last update
Mar 18, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: ETBX-011 · GI-4000 · ETBX-051 · ETBX-061 · Yeast-CEA vaccine · GI-6301 · Nogapendekin alfa inbakicept

Start the discussion